Meta-Analysis of Difference between Olanzapine Combining Antidepressant and Single Antidepressant in Treatment of Depression

Objective To assess the difference in changes of symptoms, effective rate and full remission rate between Ziprasidone combining antidepressants and single antidepressant in the treatment of treatment-resistant depression（TRD）. Methods 8 studies meeting our criteria were analyzed by evidence-based medicine, comparing the difference in changes of symptoms, efficacy rate and full remission rate. Results The lower depressive symptoms in Ziprasidone group comparing controls were found （Z=15.84, P< 0.01, WMD=-3.83, 95%CI -4.30~-3.36）. The very significant higher effective rate and full remission rate in Ziprasidone group comparing controls were found （63.3% vs. 45.7%, Z=4.31, P< 0.000 1, OR=2.25, 95%CI 1.56~3.26; 35.6% vs. 19.1%, Z=4.44, P< 0.000 01, OR=2.58, 95%CI 1.70~3.91）. Conclusion It can promote therapeutic efficacy of patients with treatment-resistant depression, combining antidepressants with Ziprasidone.